Physician profile

Carlyn E Tackett

Family · Sapulpa, OK

NPI 1720610587

$62.99

in general payments reported to CMS, 2019-2025

3 companies · $19.90 in 2025

The $19.90 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$62.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Acella Pharmaceuticals, LLC $29.53 2023 NP Thyroid 60
Antares Pharma, INC. $19.90 2025 Xyosted
Azurity Pharmaceuticals, INC. $13.56 2023 Adthyza

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Carlyn E Tackett

$62.99

in general payments reported 2019-2025

Years
2023-2025
Top company
Acella Pharmaceuticals, LLC
Context
The $19.90 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).

https://glasscript.com/doctor/10698848/carlyn-e-tackett

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.